M.D. Anderson Cancer Center: Leukemia, Myeloid, Chronic-Phase trials
The registry lists 17 Leukemia, Myeloid, Chronic-Phase studies with M.D. Anderson Cancer Center as lead sponsor. 2 are open to participants now and 5 have results posted.
Phase 1 3Phase 2 14Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Personalized NK Cell Therapy in CBTRecruitingNCT02727803Phase 2
- Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or NilotinibRecruitingNCT01746836Phase 2
- Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI FailureTerminatedNCT02906696Phase 2Results posted
- Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase TherapyCompletedNCT01428635Phase 2/3Results posted
- Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00254423Phase 2Results posted
- Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)CompletedNCT00129740Phase 2Results posted
- Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-CTerminatedNCT00038649Phase 2Results posted
- ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic PhaseActive, not recruitingNCT05007873Phase 2
- Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
- Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous LeukemiaActive, not recruitingNCT02689440Phase 2
- NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
- Late Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT01092741Phase 2
- Therapy of Early Chronic Phase CML With GleevecCompletedNCT00048672Phase 2
- Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00040105Phase 1
- Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous TreatmentWithdrawnNCT00006091Phase 2
- Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00003239Phase 2
- Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous LeukemiaCompletedNCT00002833Phase 2